# US 2016/0354350 A1 · Compositions and methods for treating conditions related to increased eosinophils

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0354350 A1
- Document ID: US20160354350A1
- Status: Published application
- Kind: A1
- Application number: 15/181,526
- Filed: 2016-06-14
- Published: 2016-12-08
- Earliest claimed: 2013-07-12
- Assignees: Knopp Biosciences LLC
- Applicants: Knopp Biosciences LLC
- Inventors: Michael E. BOZIK; Gregory HEBRANK; Wildon FARWELL; Thomas PETZINGER, JR.; Steven DWORETZKY
- Web page: https://patentgrep.com/patent/US20160354350A1

## CPC

- A61K 31/428: condensed with carbocyclic rings
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Disclosed herein are methods of treating diseases associated with increased numbers of eosinophils basophils, and/or neutrophils with R(+) pramipexole.

## Claims

### Claim 1

A method of treating a condition characterized by increased numbers of eosinophils in a subject comprising:
administering to a subject in need thereof a therapeutically effective amount of R(+) pramipexole or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the condition is selected from incomplete Kawasaki disease (iKd), Behcet Disease, tonsolitis and cervical adenitis, Graves' ophthalmology, Churg Strauss, nasal polyposis, atopic dermatitis, eosinophilic esophagitis, hypereosinophilic syndrome, asthma, allergic rhinitis, non-allergic rhinitis with eosinophilia syndrome, eosinophilic granuloma (histiocytosis X), eosinophilic polymyositis, chronic eosinophilic pneumonia, eosinophilic gastroenteritis, aggressive systemic mastocytosis, Gleich's syndrome, eosinophilia myalgia syndrome, Omenn syndrome, hyper-IgE syndrome, eosinophilic leukemia, and inflammatory bowel diseases.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the condition is hypereosinophilic syndrome.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the condition is an inflammatory condition.

### Claim 5 (depends on 1)

The method of claim 1, wherein the condition characterized by increased numbers of eosinophils is characterized by eosinophil numbers above about 450 cells per microliter in the peripheral blood.

### Claim 6 (depends on 1)

The method of claim 1, wherein the therapeutically effective amount is from about 50 mg to about 1,500 mg per day.

### Claim 7 (depends on 1)

The method of claim 1, wherein the therapeutically effective amount is from about 150 mg to about 1,500 mg per day.

### Claim 8 (depends on 1)

The method of claim 1, wherein the therapeutically effective amount is from about 150 mg to about 300 mg per day.

### Claim 9 (depends on 1)

The method of claim 1, wherein administering comprises administering a fraction of the daily dose two or more times per day.

### Claim 10 (depends on 1)

The method of claim 1, wherein administering comprises administering a dose equal to about half of a daily dose twice per day.

### Claim 11 (depends on 10)

The method of claim 10, wherein the dose is administered every 12 hours.

### Claim 12 (depends on 1)

The method of claim 1, wherein administering comprises administering about 150 mg two times per day.

### Claim 13 (depends on 1)

The method of claim 1 further comprising monitoring the patient.

### Claim 14 (depends on 1)

The method of claim 1 further comprising monitoring the patient for neutropenia.

### Claim 15 (depends on 1)

The method of claim 1, further comprising an induction step.

### Claim 16 (depends on 15)

The method of claim 15, wherein said induction step comprises administering a second therapeutic agent that is capable of decreasing eosinophil levels.

### Claim 17 (depends on 15)

The method of claim 15, wherein said induction step is from about 1 week to about 6 months.

### Claim 18 (depends on 1)

The method of claim 1, wherein said therapeutically effective amount of R(+) pramipexole is about 1,200 mg.

### Claim 19 (depends on 1)

The method of claim 1, wherein said therapeutically effective amount of R(+) pramipexole is about 1,500 mg.

### Claim 20

A method of treating a condition characterized by increased numbers of basophils in a subject, comprising:
administering to a subject in need thereof, a therapeutically effective amount of R(+) pramipexole or a pharmaceutically acceptable salt thereof.

### Claim 21 (depends on 20)

The method according to claim 20, wherein the condition is selected from allergy, and herpes stromal keratitis.

### Claim 22 (depends on 20)

The method according to claim 20, wherein the condition is an inflammatory condition.

### Claim 23 (depends on 20)

The method of claim 20, wherein the condition characterized by increased numbers of basophils is characterized by eosinophil numbers above about 200 cells per microliter in the peripheral blood.

### Claim 24 (depends on 20)

The method of claim 20, wherein the therapeutically effective amount is from about 50 mg to about 1,500 mg per day.

### Claim 25 (depends on 20)

The method of claim 20, wherein the therapeutically effective amount is from about 150 mg to about 1,500 mg per day.

### Claim 26 (depends on 20)

The method of claim 20, wherein the therapeutically effective amount is from about 150 mg to about 300 mg per day.

### Claim 27 (depends on 20)

The method of claim 20, wherein administering comprises administering a fraction of the daily dose two or more times per day.

### Claim 28 (depends on 20)

The method of claim 20, wherein administering comprises administering a dose equal to about half of a daily dose twice per day.

### Claim 29 (depends on 28)

The method of claim 28, wherein the dose is administered every 12 hours.

### Claim 30 (depends on 20)

The method of claim 20, wherein administering comprises administering about 150 mg two times per day.

### Claim 31 (depends on 20)

The method of claim 20, further comprising monitoring the patient.

### Claim 32 (depends on 20)

The method of claim 20, further comprising monitoring the patient for neutropenia.

### Claim 33 (depends on 20)

The method of claim 20, further comprising an induction step.

### Claim 34 (depends on 33)

The method of claim 33, wherein said induction step comprises administering a second therapeutic agent that is capable of decreasing eosinophil levels.

### Claim 35 (depends on 33)

The method of claim 33, wherein said induction step is from about 1 week to about 6 months.

### Claim 36 (depends on 24)

The method of claim 24, wherein said therapeutically effective amount of R(+) pramipexole is about 1,200 mg.

### Claim 37 (depends on 24)

The method of claim 24, wherein said therapeutically effective amount of R(+) pramipexole is about 1,500 mg.

### Claim 38

A method of treating a condition characterized by increased numbers of neutrophils in a subject, comprising:
administering to a subject in need thereof, a therapeutically effective amount of R(+) pramipexole or a pharmaceutically acceptable salt thereof.

### Claim 39 (depends on 38)

The method according to claim 38, wherein the condition is selected from drug induced injuries, cutaneous reactions and disorders including bullous pemphigoid, chronic granulomatous disease, vasculitides including Wegener's and ANCA-associated vasculitis, intracerebral hemorrhage, spinal cord injury, traumatic brain injury, multiple sclerosis, neuromyelitis optica, immune-mediated neurologic disorders, inflammatory bowel disease, respiratory disorders including asthma and COPD, autoimmune disorders including IDDM and SLE and rheumatoid arthritis, non-insulin dependent diabetes, herpes stromal keratitis and neurodegenerative diseases.

### Claim 40 (depends on 38)

The method according to claim 38, wherein the condition is an inflammatory condition.

### Claim 41 (depends on 38)

The method of claim 38, wherein the condition characterized by increased numbers of neutrophils is characterized by eosinophil numbers above about 7,700 cells per microliter in the peripheral blood.

### Claim 42 (depends on 38)

The method of claim 38, wherein the therapeutically effective amount is from about 50 mg to about 1,500 mg per day.

### Claim 43 (depends on 38)

The method of claim 38, wherein the therapeutically effective amount is from about 150 mg to about 1,500 mg per day.

### Claim 44 (depends on 38)

The method of claim 38, wherein the therapeutically effective amount is from about 150 mg to about 300 mg per day.

### Claim 45 (depends on 38)

The method of claim 38, wherein administering comprises administering a fraction of the daily dose two or more times per day.

### Claim 46 (depends on 38)

The method of claim 38, wherein administering comprises administering a dose equal to about half of a daily dose twice per day.

### Claim 47 (depends on 46)

The method of claim 46, wherein the dose is administered every 12 hours.

### Claim 48 (depends on 38)

The method of claim 38, wherein administering comprises administering about 150 mg two times per day.

### Claim 49 (depends on 38)

The method of claim 38, further comprising monitoring the patient.

### Claim 50 (depends on 38)

The method of claim 38, further comprising monitoring the patient for neutropenia.

### Claim 51 (depends on 38)

The method of claim 38, further comprising an induction step.

### Claim 52 (depends on 51)

The method of claim 51, wherein said induction step comprises administering a second therapeutic agent that is capable of decreasing eosinophil levels.

### Claim 53 (depends on 51)

The method of claim 51, wherein said induction step is from about 1 week to about 4 months.

### Claim 54 (depends on 38)

The method of claim 38, wherein said therapeutically effective amount of R(+) pramipexole is about 1,200 mg.

### Claim 55 (depends on 38)

The method of claim 38, wherein said therapeutically effective amount of R(+) pramipexole is about 1,500 mg.
